Two decisions by the British Appeal Court raise questions about the allowable breadth of biotechnology patents, but point to the charges patent-holders should be free to make.
Article PDF
Rights and permissions
About this article
Cite this article
More patent troubles about genes. Nature 372, 485 (1994). https://doi.org/10.1038/372485a0
Issue Date:
DOI: https://doi.org/10.1038/372485a0